Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis .
CONCLUSION: According to the network meta-analysis, MYL-1401O biosimilar is as effective as its originator in terms of HR of PFS.
.
PMID: 30574866 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | European Medicines Agency (EMA) | Herceptin | Men